|
|
|
| Safety and efficacy of pregabalin combined with tramadol in treatment of intractable postherpetic neuralgia |
| LI Jing1,YU Yanbo2,MENG Taojiang3,and CHEN Ting4 |
1.Department of Pain Management, Hainan Provincial Corps Hospital, Chinese People’s Armed Police Force, Haikou 570203, China;
2. Department of Pain Management, the First Affiliated Hospital of Nanchang University, Nanchang 330006, China;
3.Sanya Sanatorium,Chinese People’s Armed Police Force, Sanya 572023,China;
4.Wuxi Red Cross Central Blood Station,Wuxi 214021,China |
|
|
|
|
Abstract Objective To evaluate the clinical efficacy and safety of pregabalin combined with tramadol in the treatment of patients with postherpetic neuralgia (PHN) caused by refractory herpes zoster(the pain lasted more than 3 months).Methods Fifty-six patients with PHN caused by refractory herpes zoster were randomly divided into two groups: treatment group (30 patients) and control group (26 patients). The treatment group was given pregabalin, 75-150 mg BID combined with tramadol 100 mg BID for six weeks. The control group received tramadol 100 mgBID for six weeks. The degree of pain before and after treatment was evaluated using the Visual analogue scale (VAS), while the adverse effects were observed.Results After six weeks of treatment, the VAS scores of both groups were significantly deceased, especially in the treatment group (P<0.05).The efficacy in the treatment group (76.7%) was significantly different from that in the control group (46.1%)(P<0.01). In this study, adverse effects of pregabalin were mainly manifested as dizziness, drowsiness and peripheral edema, which were dose related.Conclusions It is safe and effective to treat PHN caused by refractory herpes zoster with pregabalin combined with tramadol.
|
|
Received: 05 January 2017
|
|
|
|
|
|
| [1] |
范永龙,蔡 卉.加巴喷丁联合针灸、通络活血止痛汤治疗带状疱疹后遗神经痛疗效观察[J].江西医药,2011,46(6):561-562.
|
| [2] |
Wang W Y, Liu S H, Lin M Y, et al. Initial presentation sites as predictors of herpes zoster complications: a nationwide cohort study[J]. PLoS One, 2016, 11(10): e0164019.
|
| [3] |
Mallick-Searle T, Snodgrass B, Brant J M. Postherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacology[J]. J Multidiscip Healthc, 2016, 2016(9): 447-454.
|
| [4] |
Dworkin R H, O’Connor A B, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update [J]. Mayo Clin Proc, 2010, 85(3 Suppl): S3-14.
|
| [5] |
Hadley G R, Gayle J A, Ripoll J, et al. Post-herpetic Neuralgia: a review [J]. Curr Pain Headache Rep, 2016, 20(3): 17.
|
| [6] |
Gan E Y, Tian E A, Tey H L. Management of herpes zoster and post-herpetic neuralgia. Am J Clin Dermatol, 2013, 14(2):77-85.
|
| [7] |
Choi B, Rowbothara M C. Effect of adrengergic receptor activation on post-herpetic neuralgia pain and sensory disturbances [J]. Pain, 1997, 69(1-2): 55-56.
|
| [8] |
皮铎波, 沈迎雁, 岳建宁,等. 椎旁脊神经根阻滞联合普瑞巴林治疗带状疱疹后神经痛的临床疗效[J]. 中国疼痛医学杂志, 2013, 19(2): 127-128.
|
| [9] |
陈 嫄, 陈春富. 普瑞巴林耐受不良及成瘾性[J]. 国际神经病学神经外科学杂志, 2014, 41(2): 189-192.
|
| [10] |
Semel D, MurphyT K, Zlateva G, et al. Evalution of the safety and efficacy of pregabalin in older patients with neropathic pain: results from a pooled analysis of 11 clinics studies [J]. BMCF Am Pract, 2010, 11(5): 85.
|
|
|
|
2017, Vol. 28 
